HK Stock MarketDetailed Quotes

09969 INNOCARE

Watchlist

4.450
+0.060+1.37%

Market Closed Apr 26 16:08 CST

7.84BMarket Cap-11265P/E (TTM)

INNOCARE Stock Forum

INNOCARE

Mar 18 09:57

ColumnsInnoCare to Host 2023 Earnings Call on March 28, 2024

$INNOCARE(09969.HK)$；$InnoCare Pharma(688428.SH)$

INNOCARE

Mar 13 08:32

ColumnsInnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma in China

InnoCare Pharma ($INNOCARE(09969.HK)$；$InnoCare Pharma(688428.SH)$), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor...

INNOCARE

Mar 11 08:39

ColumnsLatest data of InnoCare's ICP-332 for the Treatment of Atopic Dermatitis Presented at LBA Session of 2024 AAD

InnoCare Pharma ($INNOCARE(09969.HK)$; $InnoCare Pharma(688428.SH)$), a commercial-stage biotech company, announced today that the latest data of the novel TYK2 inhibitor ICP-332 developed by the Company for the treatment of patients with moderate-to-severe atopic dermatitis (AD) has been released at the 2024 American Academy of Dermatology (AAD) Annual Meeting as a late-breaking oral ...

Moomoo AI

Feb 15 08:21

InnoCare Pharma's balance sheet indicates it can handle adversity with more cash than debt. Despite an EBIT loss last year, solid revenue growth may suggest a path to profitability.

Does InnoCare Pharma (HKG:9969) Have A Healthy Balance Sheet?

INNOCARE

Jan 24 08:42

ColumnsInnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China

InnoCare Pharma ($INNOCARE(09969.HK)$；$InnoCare Pharma(688428.SH)$), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first pediatric patient has been dosed in clinical trial with its second generation pan-TRK inhibitor zurletrectinib at Sun Yat-sen University Cancer Center. This is the first time that zurletrec...

INNOCARE

Jan 22 09:44

ColumnsInnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area’s Early Access Program

InnoCare ($INNOCARE(09969.HK)$；$InnoCare Pharma(688428.SH)$) today announced that tafasitamab (Minjuvi®) in combination with lenalidomide has been recently approved by the Medical Products Administration of Guangdong Province, under the early access program in Guangdong-Hong Kong-Macao Greater Bay Area (“Gre...

INNOCARE

Jan 16 11:13

ColumnsInnoCare Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA

InnoCare Pharma ($INNOCARE(09969.HK)$; $InnoCare Pharma(688428.SH)$), a commercial-stage biotech company, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the Company's B-cell lymphoma-2 (BCL2) inhibitor, ICP-248. This is InnoCare’s fifth innovative drug to enter the clinical stage in the U.S.
This is a Phase I study to evaluate the...

INNOCARE

Dec 28, 2023 08:50

ColumnsInnoCare to Present at the 42nd Annual J.P. Morgan Healthcare Conference

InnoCare Pharma ($INNOCARE(09969.HK)$$InnoCare Pharma(688428.SH)$) announced today that Dr. Jasmine Cui, Co-founder, Chairwoman and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference, at 08:30 AM, January 10, 2024, U.S. Pacific Standard Time (00:30 AM, January 11, 2023, Beijing Time), to update the Company’s latest development.
The J.P. Morgan Healthcare Conference is the most influential event for the...

INNOCARE

Dec 18, 2023 08:50

ColumnsInnoCare Appoints Xin Fu as Chief Financial Officer

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that the Company appointed Mr. Xin Fu, who has extensive finance-related experience, as the Chief Financial Officer (CFO). He reports to the Co-founder, Chairwoman and CEO of InnoCare Pharma, Dr. Jasmine Cui. Mr. Fu is responsible for the Company’s growth strategy, financial management, investment & financin...

INNOCARE

Dec 17, 2023 16:15

ColumnsInnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-332 Meet Primary Endpoint in Patients with Atomic Dermatitis

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that phase II clinical study results of novel TYK2 (Tyrosine Kinase 2) inhibitor ICP-332 met primary endpoint in adult patients with moderate-to-severe atopic dermatitis (AD).
ICP-332 in AD patients treated for 4 weeks...

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall